白细胞介素-2信号通过淋巴-树突状细胞通路汇聚促进抗癌免疫
肿瘤浸润树突状细胞(DC)与有效抗癌免疫及抗PD-1疗效相关,但其扩增驱动因素不明。研究发现IL-2通过固有和适应性淋巴样细胞刺激小鼠和人类DC形成,IL-2受体偏向性IL-2使1型DC(包括迁移性和交叉提呈亚群)及2型DC显著扩增。机制上IL-2信号刺激固有淋巴样细胞、NK细胞和T细胞合成FLT3L、CSF-2和TNF,这些细胞因子冗余性导致DC扩增和活化,改善抗原加工并与有利抗癌反应相关。
要点
- IL-2通过刺激淋巴样细胞产生FLT3L、CSF-2和TNF间接扩增DC。
- IL-2受体偏向性IL-2可显著扩增1型和2型DC亚群。
- DC扩增改善抗原加工并与小鼠和患者有利抗癌反应相关。
核心结论
- IL-2免疫治疗通过刺激DC扩增和活化增强肿瘤免疫原性,从而促进抗癌免疫。
研究设计与样本
- 研究在小鼠和人类中开展,包括临床试验中给人类施用IL-2及给小鼠施用IL-2受体偏向性IL-2。
主要发现
- IL-2通过固有和适应性淋巴样细胞刺激DC形成,此DC增加改善抗癌免疫。
- 临床试验中给人类施用IL-2及给小鼠施用IL-2R偏向性IL-2导致1型DC(包括迁移性和交叉提呈亚群)和2型DC显著扩增,而DC前体和成熟DC均无功能性IL-2R。
- 机制上IL-2信号刺激固有淋巴样细胞、NK细胞和T细胞合成FLT3L、CSF-2和TNF,这些细胞因子冗余性导致DC扩增和活化,改善抗原加工并与小鼠和患者有利抗癌反应相关。
临床怎么用
- IL-2免疫治疗可通过扩增DC使肿瘤更具免疫原性,可能增强抗癌免疫应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tumor-infiltrating dendritic cells (DCs) correlate with effective anticancer immunity and improved responsiveness to anti-PD-1 checkpoint immunotherapy. However, the drivers of DC expansion and intratumoral accumulation are ill-defined. We found that interleukin-2 (IL-2) stimulated DC formation through innate and adaptive lymphoid cells in mice and humans, and this increase in DCs improved anticancer immunity. Administration of IL-2 to humans within a clinical trial and of IL-2 receptor (IL-2R)-biased IL-2 to mice resulted in pronounced expansion of type 1 DCs, including migratory and cross-presenting subsets, and type 2 DCs, although neither DC precursors nor mature DCs had functional IL-2Rs. In mechanistic studies, IL-2 signals stimulated innate lymphoid cells, natural killer cells, and T cells to synthesize the cytokines FLT3L, CSF-2, and TNF. These cytokines redundantly caused DC expansion and activation, which resulted in improved antigen processing and correlated with favorable anticancer responses in mice and patients. Thus, IL-2 immunotherapy-mediated stimulation of DCs contributes to anticancer immunity by rendering tumors more immunogenic.
引用
- Raeber ME, Rosalia RA, Schmid D, et al. Interleukin-2 signals converge in a lymphoid-dendritic cell pathway that promotes anticancer immunity. Sci Transl Med. 2020. PMID: 32938795. doi:10.1126/scitranslmed.aba5464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。